LSD

Psilocybin is a naturally occurring psychedelic compound found in over 200 species of mushrooms. When ingested, it converts to psilocin, which activates serotonin receptors in the brain, particularly the 5-HT2A receptor. This leads to altered perception, enhanced emotional processing, and increased neuroplasticity. Research shows psilocybin creates rapid and durable antidepressant effects, with single doses producing symptom reductions lasting weeks to months. Compass Pathways' COMP360, a synthetic psilocybin formulation, successfully met primary endpoints in two Phase 3 trials for treatment-resistant depression in 2026, showing a 3.8-point MADRS reduction compared to control doses. The compound appears to work by disrupting rigid thought patterns and promoting cognitive flexibility, while simultaneously reducing activity in the brain's default mode network, which is often hyperactive in depression. Johns Hopkins, Imperial College London, and other leading institutions have published groundbreaking studies demonstrating psilocybin's efficacy for depression, anxiety in cancer patients, addiction, and obsessive-compulsive disorder. The therapeutic effects appear enhanced when combined with psychotherapy and intention-setting.

DMT (N,N-Dimethyltryptamine) and its close relative 5-MeO-DMT are among the most potent psychedelics known, producing intense but brief experiences. N,N-DMT, found in many plants and the active component of ayahuasca, creates vivid geometric patterns, encounters with seemingly autonomous entities, and profound shifts in consciousness lasting 15-30 minutes when smoked or vaporized. 5-MeO-DMT, found naturally in certain plants and the venom of the Sonoran Desert toad (Incilius alvarius), produces a more unified, often ineffable "white light" experience characterized by ego dissolution and feelings of cosmic unity. Clinical research on 5-MeO-DMT has accelerated dramatically, with multiple Phase 1/2 trials active in 2024-2025. Beckley Psytech's Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression showed rapid, durable antidepressant effects with MADRS reductions of 10.8-11.1 points at day 8, generally well-tolerated with no serious adverse events. Sublingual formulations are also in trials for anxiety and depression. Imperial College London reported that a single dose of ayahuasca's DMT compound produced significant and lasting depression relief in 2026 research. The rapid onset and short duration make DMT particularly interesting for clinical settings, as the entire experience can occur within a supervised session.